Postrock Partners LLC Takes $725,000 Position in Danaher Co. (NYSE:DHR)

Postrock Partners LLC acquired a new stake in Danaher Co. (NYSE:DHR) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 3,160 shares of the conglomerate’s stock, valued at approximately $725,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DHR. Heck Capital Advisors LLC bought a new stake in shares of Danaher in the fourth quarter valued at about $27,000. Decker Retirement Planning Inc. bought a new stake in Danaher in the 4th quarter valued at approximately $31,000. Golden State Wealth Management LLC acquired a new position in Danaher during the 4th quarter worth approximately $31,000. Strategic Financial Concepts LLC bought a new position in shares of Danaher during the 4th quarter worth approximately $31,000. Finally, Pineridge Advisors LLC raised its holdings in shares of Danaher by 63.3% in the fourth quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock valued at $34,000 after purchasing an additional 57 shares during the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 11.10% of the company’s stock.

Danaher Stock Down 0.5 %

DHR stock opened at $203.96 on Friday. The business’s fifty day moving average price is $220.55 and its two-hundred day moving average price is $241.22. The stock has a market capitalization of $145.77 billion, a price-to-earnings ratio of 38.63, a PEG ratio of 2.66 and a beta of 0.82. Danaher Co. has a fifty-two week low of $196.80 and a fifty-two week high of $281.70. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period in the prior year, the company posted $2.09 earnings per share. On average, equities analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a $0.32 dividend. The ex-dividend date is Friday, March 28th. This is a boost from Danaher’s previous quarterly dividend of $0.27. This represents a $1.28 annualized dividend and a yield of 0.63%. Danaher’s payout ratio is currently 24.24%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on DHR shares. Citigroup decreased their target price on shares of Danaher from $285.00 to $265.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Raymond James restated a “market perform” rating on shares of Danaher in a report on Monday, February 3rd. The Goldman Sachs Group set a $250.00 target price on Danaher in a report on Wednesday, January 15th. Barclays decreased their price target on Danaher from $275.00 to $240.00 and set an “equal weight” rating for the company in a research note on Thursday, January 30th. Finally, Wells Fargo & Company dropped their price objective on Danaher from $280.00 to $240.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 30th. Seven equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $278.00.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.